Oncology Central

Safety of HTX-019 (IV aprepitant) and fosaprepitant in healthy subjects

0

Chemotherapy-induced nausea and vomiting (CINV) affects approximately 60–80% of oncology patients, despite the use of prophylactic antiemetics. This side effect remains among the most concerning for both clinicians and patients and may increase the likelihood of patients discontinuing chemotherapy, with the potential for adverse effects on survival outcomes.

In this new article published in Future Oncology, Ottoboni et al. report on the safety of a novel and recently FDA-approved polysorbate 80‒ and synthetic surfactant-free intravenous formulation of the neurokinin 1 receptor antagonist aprepitant (HTX-019). The team analyzed pooled safety data from two open-label, randomized studies, which each included a total of 200 healthy subjects receiving HTX-019 130 mg (30-minute infusion) and fosaprepitant 150 mg (20- or 30-minute infusion) with a 7- or 14-day washout between doses. HTX-019 was well tolerated and may provide a safer aprepitant formulation than fosaprepitant for CINV prevention.

View full text

Graphical abstract

fon-2018-0311ga.eps

Share:

Insights

Videos

News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.